Alternative Splicing: A Potential Therapeutic Target in Hematological Malignancies

Overview

Journal Hematol Rep

Publisher MDPI

Date 2024 Nov 25

PMID 39584923

Authors

Gazmend Temaj

Silvia Chichiarelli

Sarmistha Saha

Pelin Telkoparan-Akillilar

Nexhibe Nuhii

Rifat Hadziselimovic

Luciano Saso

Affiliations

Soon will be listed here.

Abstract

Leukemia represents the most prevalent malignancy in children, constituting 30% of childhood cancer cases, with acute lymphoblastic leukemia (ALL) being particularly heterogeneous. This paper explores the role of alternative splicing in leukemia, highlighting its significance in cancer development and progression. Aberrant splicing is often driven by mutations in splicing-factor genes, which can lead to the production of variant proteins that contribute to oncogenesis. The spliceosome, a complex of small nuclear RNAs and proteins, facilitates RNA splicing, a process critical for generating diverse mRNA and protein products from single genes. Mutations in splicing factors, such as U2AF1, SF3B1, SRSF2, ZRSR2, and HNRNPH1, are frequently observed across various hematological malignancies and are associated with poor prognosis and treatment resistance. This research underscores the necessity of understanding the mechanisms of RNA splicing dysregulation in order to develop targeted therapies to correct these aberrant processes, thereby improving outcomes for patients with leukemia and related disorders.

References

Penkert J, Schmidt G, Hofmann W, Schubert S, Schieck M, Auber B . Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity. Breast Cancer Res. 2018; 20(1):87. PMC: 6081832. DOI: 10.1186/s13058-018-1011-1. View

Wu S, Kuo Y, Hou H, Li L, Tseng M, Huang C . The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood. 2012; 120(15):3106-11. DOI: 10.1182/blood-2012-02-412296. View

Garcia-Ruiz C, Martinez-Valiente C, Cordon L, Liquori A, Fernandez-Gonzalez R, Pericuesta E . Concurrent Zrsr2 mutation and Tet2 loss promote myelodysplastic neoplasm in mice. Leukemia. 2022; 36(10):2509-2518. PMC: 9522584. DOI: 10.1038/s41375-022-01674-2. View

Komeno Y, Huang Y, Qiu J, Lin L, Xu Y, Zhou Y . SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing. Mol Cell Biol. 2015; 35(17):3071-82. PMC: 4525309. DOI: 10.1128/MCB.00202-15. View

Bessa C, Matos P, Jordan P, Goncalves V . Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics. Int J Mol Sci. 2020; 21(23). PMC: 7729450. DOI: 10.3390/ijms21239032. View

Graveley B, Maniatis T . Arginine/serine-rich domains of SR proteins can function as activators of pre-mRNA splicing. Mol Cell. 1998; 1(5):765-71. DOI: 10.1016/s1097-2765(00)80076-3. View

Liang Y, Tebaldi T, Rejeski K, Joshi P, Stefani G, Taylor A . SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells. Leukemia. 2018; 32(12):2659-2671. PMC: 6274620. DOI: 10.1038/s41375-018-0152-7. View

Van Nostrand E, Freese P, Pratt G, Wang X, Wei X, Xiao R . A large-scale binding and functional map of human RNA-binding proteins. Nature. 2020; 583(7818):711-719. PMC: 7410833. DOI: 10.1038/s41586-020-2077-3. View

Patnaik M, Lasho T, Finke C, Hanson C, Hodnefield J, Knudson R . Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance. Am J Hematol. 2013; 88(3):201-6. DOI: 10.1002/ajh.23373. View

10.

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

11.

Kitamura K, Nimura K . Regulation of RNA Splicing: Aberrant Splicing Regulation and Therapeutic Targets in Cancer. Cells. 2021; 10(4). PMC: 8073995. DOI: 10.3390/cells10040923. View

12.

Lasho T, Jimma T, Finke C, Patnaik M, Hanson C, Ketterling R . SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood. 2012; 120(20):4168-71. DOI: 10.1182/blood-2012-05-429696. View

13.

Zhang Q, Ai Y, Abdel-Wahab O . Molecular impact of mutations in RNA splicing factors in cancer. Mol Cell. 2024; 84(19):3667-3680. PMC: 11455611. DOI: 10.1016/j.molcel.2024.07.019. View

14.

Masaki S, Ikeda S, Hata A, Shiozawa Y, Kon A, Ogawa S . Myelodysplastic Syndrome-Associated SRSF2 Mutations Cause Splicing Changes by Altering Binding Motif Sequences. Front Genet. 2019; 10:338. PMC: 6476956. DOI: 10.3389/fgene.2019.00338. View

15.

Cilloni D, Itri F, Bonuomo V, Petiti J . Mutations in Hematological Malignancies. Cancers (Basel). 2022; 14(19). PMC: 9563056. DOI: 10.3390/cancers14194927. View

16.

Ren P, Lu L, Cai S, Chen J, Lin W, Han F . Alternative Splicing: A New Cause and Potential Therapeutic Target in Autoimmune Disease. Front Immunol. 2021; 12:713540. PMC: 8416054. DOI: 10.3389/fimmu.2021.713540. View

17.

Wang L, Lawrence M, Wan Y, Stojanov P, Sougnez C, Stevenson K . SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011; 365(26):2497-506. PMC: 3685413. DOI: 10.1056/NEJMoa1109016. View

18.

Zhao Y, Cai W, Hua Y, Yang X, Zhou J . The Biological and Clinical Consequences of RNA Splicing Factor U2AF1 Mutation in Myeloid Malignancies. Cancers (Basel). 2022; 14(18). PMC: 9496927. DOI: 10.3390/cancers14184406. View

19.

Damm F, Kosmider O, Gelsi-Boyer V, Renneville A, Carbuccia N, Hidalgo-Curtis C . Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. 2012; 119(14):3211-8. DOI: 10.1182/blood-2011-12-400994. View

20.

Kim E, Ilagan J, Liang Y, Daubner G, Lee S, Ramakrishnan A . SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell. 2015; 27(5):617-30. PMC: 4429920. DOI: 10.1016/j.ccell.2015.04.006. View